Dyne Therapeutics, Inc.’s 2026 outlook with key DYNE-101/251 data, FDA submission plans, and extended cash runway. Click for ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236, a novel macrocyclic ...
The firm is testing the EGFR inhibitor BH-30643 in EGFR-mutated NSLC and the CLK inhibitor in certain blood cancers.
Analysis of more than 1 million people shows that mental-health disorders fall into five clusters, each of them linked to a ...
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective ...
Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular snapshots of human polynucleotide phosphorylase (hPNPase) in action, ...
From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback